Xenon

Summary

Xenon (CHEMBL1236802) is an approved small molecule (ATC N01AX15); indicated across 13 conditions including coronary artery disorder and obsessive-compulsive disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N01AX15 (+1 more)
• Indications: 13 conditions
• Clinical trials: 35
• Chemistry: 131.29 Da · Xe

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1236802
Name	Xenon
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	23991
ChEBI	CHEBI:49956
ATC	N01AX15, V04CX12
Molecular formula	Xe
Molecular weight	131.29
InChIKey	FHNFHKCVQCLJFQ-UHFFFAOYSA-N

SMILES: [Xe]

IUPAC name: xenon

Also known as: Xenon, XENON

Parent form; salt/anhydrous children: CHEMBL1200673, CHEMBL1200685, CHEMBL4594411

Patent coverage: 156,791 distinct patent families (387,752 SureChEMBL compound mentions), from 9 matched compound structure(s). One matched structure accounts for 387,725 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

13 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
coronary artery disorder	3	MONDO:0005010	EFO:0001645
obsessive-compulsive disorder	2	MONDO:0008114	EFO:0004242
delirium	2	MONDO:0045057	EFO:0009267
brain ischemia	2	MONDO:0005299	MONDO:0005299
brain injury	2	MONDO:0043510	MONDO:0043510
panic disorder	2	MONDO:0005383	EFO:0004262
obesity disorder	1	MONDO:0011122	EFO:0001073
chronic obstructive pulmonary disease	1	MONDO:0005002	EFO:0000341
major depressive disorder	0	MONDO:0002009	MONDO:0002009
cystic fibrosis	0	MONDO:0009061	MONDO:0009061
bipolar disorder	0	MONDO:0004985	MONDO:0004985

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 35.

Phase distribution

Phase	Trials
PHASE2	9
PHASE3	8
PHASE4	5
Not specified	5
PHASE1	4
EARLY_PHASE1	2
PHASE2/PHASE3	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00793663	PHASE4	COMPLETED	Depth of Hypnosis and Postoperative Nausea and Vomiting During Xenon Anaesthesia
NCT00937807	PHASE4	COMPLETED	Hemodynamic Stability During Carotid Endarterectomy.Comparison of LENOXe™ (Xenon 100% v/v) Versus Sevoflurane
NCT01167803	PHASE4	COMPLETED	Anesthesia for Obese Patients: Desflurane Versus Xenon
NCT02682758	PHASE4	COMPLETED	Influence of Xenon Anaesthesia on Transpulmonary Pressure and Tidal Volume Distribution
NCT03504033	PHASE4	WITHDRAWN	Xenon-anesthesia on Patients Undergoing Major Liver-resection
NCT03176186	PHASE3	NOT_YET_RECRUITING	Xenon for Neuroprotection During Post-Cardiac Arrest Syndrome in Comatose Survivors of an Out of Hospital Cardiac Arrest
NCT00000160	PHASE3	COMPLETED	Diabetic Retinopathy Study (DRS)
NCT00919126	PHASE3	TERMINATED	General Anesthesia With Xenon in Inspiratory Concentrations of 50% and 70% and Total I.V. Anaesthesia.
NCT01120405	PHASE3	COMPLETED	Cardiovascular Safety of Xenon in General Anaesthesia, in Patient With Cardiovascular Risk in Non Cardiac Surgery
NCT01285271	PHASE3	COMPLETED	A Pre- and Post- Coronary Artery Bypass Graft Implantation Disposed Application of Xenon
NCT01294163	PHASE3	COMPLETED	Xenon Compared to Sevoflurane and Total Intravenous Anaesthesia for Coronary Artery Bypass Graft Surgery
NCT01839084	PHASE3	COMPLETED	PaNeX: Partial Nephrectomy Under Xenon
NCT04432155	PHASE2/PHASE3	UNKNOWN	Xenon Inhalation for Treatment of Panic Disorder
NCT05335109	PHASE3	COMPLETED	Neuroprotective Effects of Xenon Treatment in Patients with Cerebral Infarction
NCT04696523	PHASE2	RECRUITING	Effect of Xenon on Brain Injury After Aneurysmal Subarachnoid Hemorrhage
NCT07435103	PHASE1/PHASE2	NOT_YET_RECRUITING	Xenon Therapy for Children With Autism Spectrum Disorder
NCT00879892	PHASE2	COMPLETED	Effect of Xenon and Therapeutic Hypothermia, on the Brain and on Neurological Outcome Following Brain Ischemia in Cardiac Arrest Patients
NCT01199276	PHASE2	COMPLETED	Hip Fracture Surgery in Elderly Patients
NCT01262729	PHASE2	TERMINATED	Xenon and Therapeutical Hypothermia After Successful Cardiopulmonary Resuscitation
NCT01696630	PHASE2	COMPLETED	Xenon Combined With Intraoperative Thoracic Epidural Analgesia
NCT01757106	PHASE2	COMPLETED	Xenon in Off-pump Coronary Artery Bypass Graft Surgery
NCT01948765	PHASE2	COMPLETED	Xenon as an Adjuvant to Propofol Anaesthesia in Patients Undergoing Off-pump Coronary Artery Bypass Graft Surgery.
NCT02098148	PHASE2	WITHDRAWN	Trial of Low-Dose Xenon For The Treatment Of Obsessive-Compulsive Disorder
NCT02768727	PHASE2	COMPLETED	A Test of Neural Inertia in Humans With Xenon
NCT01043419	PHASE1	COMPLETED	Sympathetic Neural Outflow During Xenon Anesthesia in Humans
NCT02112929	PHASE1	COMPLETED	Regional Lung Imaging Using Hyperpolarized Xenon Gas
NCT02220426	PHASE1	TERMINATED	Hyperpolarized Xenon-129 Magnetic Resonance Imaging and Spectroscopy of Brown Fat: Healthy Adult Volunteer Pilot Study
NCT02736422	PHASE1	COMPLETED	Assessment of New Magnetic Resonance Imaging (MRI) Pulse Sequences for Imaging Hyperpolarised Xenon in Lung, Heart and Brain in Volunteers
NCT03748446	EARLY_PHASE1	RECRUITING	Xenon Inhalation Therapy for Major Depressive Disorder and Bipolar Disorder
NCT06080100	EARLY_PHASE1	RECRUITING	RELIEF OF PSYCHOEMOTIONAL STRESS USING XENON SEDATION
NCT02848560	Not specified	ACTIVE_NOT_RECRUITING	Monitoring Response to Orkambi in Cystic Fibrosis Lung Disease by Inhaled Xenon MRI
NCT04793867	Not specified	RECRUITING	Regional Phenotyping of CF and Non-CF Bronchiectasis
NCT02468531	Not specified	UNKNOWN	Xenon Against Postoperative Oxygen Impairment
NCT02774096	Not specified	UNKNOWN	Cerebral and Spinal Protection of Xenon Post-conditioning in Patients Undergoing Aortic Dissection Repair
NCT03968861	Not specified	COMPLETED	Outcome After 24 Months of Participants in the TOBY Xenon Study

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).